Adverum Biotechnologies Stock Today
| ADVM Stock | USD 7.92 0.11 1.41% |
Performance0 of 100
| Odds Of DistressOver 80
|
Adverum Biotechnologies is selling at 7.92 as of the 3rd of June 2024; that is 1.41 percent increase since the beginning of the trading day. The stock's lowest day price was 7.83. Adverum Biotechnologies has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. Equity ratings for Adverum Biotechnologies are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 4th of May 2024 and ending today, the 3rd of June 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 31st of July 2014 | Category Healthcare | Classification Health Care |
Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California. Adverum Biotechnlgs operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 20.76 M outstanding shares of which 762.21 K shares are presently shorted by private and institutional investors with about 2.31 trading days to cover. More on Adverum Biotechnologies
Moving together with Adverum Stock
| 0.91 | EQ | Equillium | PairCorr |
| 0.75 | DMTK | DermTech | PairCorr |
Moving against Adverum Stock
| 0.65 | VALN | Valneva SE ADR | PairCorr |
| 0.41 | VCEL | Vericel Corp Ord | PairCorr |
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
Adverum Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Adverum Biotechnologies' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Adverum Biotechnologies or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary, Adverum Biotechnologies' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Adverum Biotechnologies' managers, analysts, and investors.
Environmental | Governance | Social |
| CEO President | Laurent Fischer | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation Analysts covering Adverum Biotechnologies report their recommendations after researching Adverum Biotechnologies' financial statements, talking to executives and customers, or listening in on Adverum Biotechnologies' conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Adverum Biotechnologies. The Adverum consensus assessment is calculated by taking the average forecast from all of the analysts covering Adverum Biotechnologies. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Financial Strength Based on the key indicators related to Adverum Biotechnologies' liquidity, profitability, solvency, and operating efficiency, Adverum Biotechnologies is not in a good financial situation at this time. It has a very high odds of going through financial crisis in July. Financial strength of Adverum Biotechnologies is based on its profitability, leverage, liquidity, source of funds, and operating efficiency.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adverum Biotechnologies' financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Adverum Biotechnologies' success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Adverum Biotechnologies' financial leverage. It provides some insight into what part of Adverum Biotechnologies' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adverum Biotechnologies (ADVM) is traded on NASDAQ Exchange in USA. It is located in 100 Cardinal Way, Redwood City, CA, United States, 94063 and employs 121 people. Adverum Biotechnologies is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 164.39 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Adverum Biotechnologies's market, we take the total number of its shares issued and multiply it by Adverum Biotechnologies's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Adverum Biotechnologies conducts business under Biotechnology sector and is part of Health Care industry. The entity has 20.76 M outstanding shares of which 762.21 K shares are presently shorted by private and institutional investors with about 2.31 trading days to cover.
Adverum Biotechnologies currently holds about 235.84 M in cash with (91.32 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.37.
Check Adverum Biotechnologies Probability Of Bankruptcy
Ownership AllocationAdverum Biotechnologies retains a total of 20.76 Million outstanding shares. The majority of Adverum Biotechnologies outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Adverum Biotechnologies to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Adverum Biotechnologies. Please pay attention to any change in the institutional holdings of Adverum Biotechnologies as this could imply that something significant has changed or is about to change at the company. Remember, it does not matter who owns the company or if the company is currently losing money. If the true value of the company is more than the market pays for it currently, you can still have a good investment opportunity.
Check Adverum Ownership Details
Adverum Stock Institutional Holders
Institutional Holdings refers to the ownership stake in Adverum Biotechnologies that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Adverum Biotechnologies' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Adverum Biotechnologies' value.| Instituion | Recorded On | Shares | |
| Morgan Stanley - Brokerage Accounts | 2024-03-31 | 562 K | |
| 5am Venture Management, Llc | 2024-03-31 | 541.7 K | |
| Laurion Capital Management Lp | 2024-03-31 | 438.9 K | |
| Soleus Capital Management, L.p. | 2023-12-31 | 425 K | |
| Venbio Select Advisor Llc | 2024-03-31 | 416.7 K | |
| Assenagon Asset Management Sa | 2024-03-31 | 358.7 K | |
| Blackrock Inc | 2024-03-31 | 316.4 K | |
| Samsara Biocapital, Llc | 2024-03-31 | 291.7 K | |
| Millennium Management Llc | 2024-03-31 | 248.6 K | |
| Commodore Capital Lp | 2023-12-31 | 10 M | |
| Versant Venture Management Llc | 2023-12-31 | 5.1 M |
Adverum Biotechnologies Historical Income Statement
Adverum Biotechnologies Income Statement is one of the three primary financial statements used for reporting Adverum's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Adverum Biotechnologies revenue and expense. Adverum Biotechnologies Income Statement primarily focuses on the company's revenues and expenses during a particular period.
At this time, Adverum Biotechnologies' Depreciation And Amortization is very stable compared to the past year. As of the 3rd of June 2024, Interest Expense is likely to grow to about 3.2 M, while Total Revenue is likely to drop about 2.8 M. View More FundamentalsAdverum Stock Against Markets
Picking the right benchmark for Adverum Biotechnologies stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Adverum Biotechnologies stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Adverum Biotechnologies is critical whether you are bullish or bearish towards Adverum Biotechnologies at a given time. Please also check how Adverum Biotechnologies' historical prices are related to one of the top price index indicators.
Be your own money manager
Our tools can tell you how much better you can do entering a position in Adverum Biotechnologies without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Sync Your Broker Now
Sync Your BrokerSync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. |
| All Next | Launch Module |
Adverum Biotechnologies Corporate Management
Elected by the shareholders, the Adverum Biotechnologies' board of directors comprises two types of representatives: Adverum Biotechnologies inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Adverum. The board's role is to monitor Adverum Biotechnologies' management team and ensure that shareholders' interests are well served. Adverum Biotechnologies' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Adverum Biotechnologies' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jim Wang | Chief Officer | Profile | |
| Andrew Ramelmeier | Chief Officer | Profile | |
| Romuald Corbau | Chief Officer | Profile | |
| Kalliopi MD | Senior Development | Profile | |
| Michael Steel | Senior Quality | Profile | |
| Brigit Riley | Chief Officer | Profile |
How to buy Adverum Stock?
Before investing in Adverum Biotechnologies, you must ensure you fully understand your financial goals and how diversified (or not) your overall investments are now. Then, after you clearly understand your investment objectives, consider investing in Adverum Biotechnologies. To buy Adverum Biotechnologies stock, you can follow these steps:- Choose a brokerage firm: You need to select a brokerage firm to buy shares of Adverum Biotechnologies. Some popular options include Charles Schwab, Fidelity, TD Ameritrade, and Robinhood.
- Open an account: Once you have chosen a brokerage firm, you will need to open an account. You will be required to provide personal information, such as your name, address, and Social Security number.
- Fund your account: You will need to deposit funds into your brokerage account to purchase Adverum Biotechnologies stock. You can do this by transferring funds from your bank account or other investment accounts.
- Place your order: Once you have located Adverum Biotechnologies stock in your brokerage account, you can place your order to buy it. You will need to specify the number of shares you want to buy and the price you are willing to pay.
- Monitor your investment: After you have purchased Adverum Biotechnologies stock, you should monitor your investment to track its performance and make informed decisions about buying, selling, or holding the stock
It's important to note that investing in stocks, such as Adverum Biotechnologies, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember various factors, including economic indicators, change in net worth, political events, company-specific news, and investor sentiment, can influence the stock market. These factors can cause fluctuations in stock prices and lead to market volatility affecting your buy or sell decision. However, volatility can also present opportunities for investors to make gains by buying stocks when prices are low and selling when they are high. It's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. For more information on how to buy Adverum Stock please use our How to Invest in Adverum Biotechnologies guide.
Already Invested in Adverum Biotechnologies?
The danger of trading Adverum Biotechnologies is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Adverum Biotechnologies is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Adverum Biotechnologies. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Adverum Biotechnologies is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Adverum Biotechnologies is a strong investment it is important to analyze Adverum Biotechnologies' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Adverum Biotechnologies' future performance. For an informed investment choice regarding Adverum Stock, refer to the following important reports: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Adverum Biotechnologies. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in real. To learn how to invest in Adverum Stock, please use our How to Invest in Adverum Biotechnologies guide.You can also try the Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..
Complementary Tools for Adverum Stock analysis
When running Adverum Biotechnologies' price analysis, check to measure Adverum Biotechnologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Adverum Biotechnologies is operating at the current time. Most of Adverum Biotechnologies' value examination focuses on studying past and present price action to predict the probability of Adverum Biotechnologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Adverum Biotechnologies' price. Additionally, you may evaluate how the addition of Adverum Biotechnologies to your portfolios can decrease your overall portfolio volatility.
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data |
Is Adverum Biotechnologies' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Adverum Biotechnologies. If investors know Adverum will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Adverum Biotechnologies listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (10.20) | Quarterly Revenue Growth (0.70) | Return On Assets (0.28) | Return On Equity (0.66) |
The market value of Adverum Biotechnologies is measured differently than its book value, which is the value of Adverum that is recorded on the company's balance sheet. Investors also form their own opinion of Adverum Biotechnologies' value that differs from its market value or its book value, called intrinsic value, which is Adverum Biotechnologies' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Adverum Biotechnologies' market value can be influenced by many factors that don't directly affect Adverum Biotechnologies' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Adverum Biotechnologies' value and its price as these two are different measures arrived at by different means. Investors typically determine if Adverum Biotechnologies is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Adverum Biotechnologies' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.